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Abstract
In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for
generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of
pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced
immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either
prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein
boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a
mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3,
monophosphoryl lipid A (MPLA) and ISCOMATRIX™ adjuvant, in the context of a previously tested pentavalent
HIV-1 Env DNA prime-protein boost formulation, DP6-001. Our data revealed that the candidate adjuvants in the
context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles. Such
information will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with
the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of an
adjuvant. More significantly, results reported here will add to the knowledge on how to include an adjuvant in the
context of a heterologous prime-protein boost vaccination strategy in general.
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Introduction
Recently, the RV144 clinical trial using a viral vector prime-
recombinant protein boost vaccine demonstrated a low level,
but statistically significant protection against HIV-1 infection in
Thai volunteers [1–4]. The RV144 trial employed a canarypox
viral vector ALVAC, encoding HIV-1 antigens env, gag, and
pol, as a prime, followed by a boost with bi-clade AIDSVAX B/E
recombinant gp120 protein boost formulated with adjuvant
Al(OH)3. After extensive follow-up studies, new data are
emerging to suggest that antibodies against certain critical
areas of HIV-1 envelope proteins are responsible for
protection; however, the antibody responses in the RV144 trial
were not long lasting, which may have led to reduced
protection during the clinical trial observation period.
Following the results of the RV144 trial, especially given the
renewed interest of including recombinant Env proteins in the
future HIV-1 vaccine development, the study of adjuvants is
gaining more momentum as adjuvant is a critical component of
most licensed recombinant protein-based human vaccine. A
more immunogenic adjuvant than Al(OH)3 may provide
enhanced and long lasting antibody responses, which may
improve the level of protection compared to that observed in
the RV144 trial.
A key consideration in vaccine development is enhancing
immunogenicity while mitigating associated adverse effects.
The inclusion of adjuvants in vaccine formulations has long
been a method of improving vaccine efficacy, but these
adjuvants are not without risk of eliciting local and systemic
adverse effects. HIV-1 recombinant Env protein-based
vaccines are now primarily being used as a boost component
in emerging HIV-1 vaccine strategies. Thus, it is very important
scientifically to examine how an adjuvant works when it is
formulated with Env proteins, and in the context of hosts who
have been primed by a gene-based vaccine (such as viral
vector or DNA vaccine) encoding antigens similar to the boost.
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Our group has demonstrated the high immunogenicity of the
pentavalent DNA prime-protein boost HIV-1 vaccine
formulation, DP6-001, in preclinical and phase I clinical trials
[5–7]. The saponin adjuvant QS-21, derived from Quillaia
saponaria, was included as part of the Env protein boost in the
phase I clinical study of DP6-001 formulation. Previously
published studies have also utilized QS-21 as part of
recombinant Env protein alone vaccines in humans,
demonstrating a potent immunogenicity allowing for reduced
antigen dose, and characterized by improved binding and
neutralizing antibody responses [8,9]. However, in these
studies QS-21 has been associated with serious local
reactions, including pain, induration, erythema, as well as
systemic adverse effects such as hypertension, myalgia,
headache, and vasovagal episodes which were rare and not
proven to be caused by QS-21 directly [8,9]. We also observed
in clinical trials of DP6-001, local skin reactions as well as rare
skin based vasculitis associated with QS-21 adjuvanted protein
boosting [6].
In the current study, the serum cytokine profiles in mice in
the context of the DP6-001 DNA prime-protein boost were
analyzed, in the context of several protein-adjuvant boost
formulations. MPLA and ISCOMATRIX™ adjuvant were
examined in formulation with the DP6-001 vaccine, along with
QS-21 and aluminum hydroxide (Al(OH)3), which were tested in
previous clinical studies of HIV-1 vaccines. Similar to QS-21,
ISCOMATRIX™ adjuvant consists of a Quillaia saponin
fraction, which is mixed with cholesterol and phospholipid
under controlled conditions to form a cage-like structure of
approximately 40nm in diameter. The ISCOMATRIX™ adjuvant
can then be formulated with virtually any antigen to make a
vaccine. Formulating saponin with cholesterol and phospholipid
appears to ameliorate the reactogenicity associated with using
free saponin, as ISCOMATRIX™ adjuvant retains the
immunogenic potency and antigen dose reduction potential of
saponin but demonstrates improved tolerability [10,11].
ISCOMATRIX™ adjuvant promotes a balanced Th1/Th2
response, as well as a uniquely strong cytotoxic T cell
response and long-lasting antibody responses in both animal
and human models [12–15]. This broad, robust activation of
adaptive immunity has made ISCOMATRIX™ adjuvant
particularly efficacious in clinical studies of anti-tumor vaccines
[16–18], as well as trials of therapeutic and protective human
papilloma virus (HPV) vaccines and influenza vaccines [19,20].
Comprehensive clinical safety data has been compiled and
reported for six clinical trials of ISCOMATRIX™ adjuvant with a
variety of antigen formulations [11].
MPLA is low-toxicity, dephosphorylated derivative of
lipopolysaccharide (LPS) [21]. MPLA, like LPS, acts via Toll-
like receptor (TLR) 4, but results in significantly less
inflammation compared to its parent molecule [21,22]. As an
adjuvant, MPLA improves vaccine-specific antibody responses,
as well as induces potent Th1 responses in preclinical and
clinical models, resulting in a complex inflammatory response
consisting of neutrophils, antigen-presenting cells (APCs), and
natural killer cells (NKs). Despite its potency, MPLA has been
well tolerated in clinical trials. Currently, MPLA is a component
of the licensed GlaxoSmithKline (GSK) human vaccines
Fendrix® for hepatitis B in combination with aluminum
phosphate and, in formulation with aluminum hydroxide in
Adjuvant System AS04, in Cervarix® for human papilloma virus
[21–23]. MPLA has also been clinically evaluated in GSK’s
AS01 adjuvant system in combination with QS-21 as a
component of a malaria vaccine [24]. Aluminum-based
adjuvants are the most widely utilized in human vaccines due
to their tolerability and consistent induction of humoral
immunity. Thus, Al(OH)3 has been included in the current study
to provide a baseline control in the generation of an acceptable
profile of tolerability [25,26].
The relative immunogenicity of our candidate adjuvants in
combination with HIV Env proteins was assessed in both
C57Bl/6 and Balb/c mice, based on a comprehensive profile of
vaccine-specific antibody and T cell responses, as well as non-
antigen specific serum cytokines detected shortly after protein
immunization. While results show that the candidate adjuvants
demonstrated comparable vaccine-specific immunogenic
potency by IgG ELISA and T cell ELISpot, the analysis of
serum cytokines allowed us to distinguish a profile of
characteristic cytokines for each adjuvant. With this
information, we will be better informed in the future for the
selection of an adjuvant as part of a prime-boost HIV-1 vaccine
formulation such as the polyvalent DNA prime- Env protein
boost shown in the current report.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and
Use Committee of the University of Massachusetts Medical
School (Protocol Number: A-925). Termination was performed
under anesthesia, and all efforts were made to minimize
suffering.
HIV-1 gp120 DNA vaccine
The gp120-expressing DNA vaccine component of the
DP6-001 formulation was composed of equal amounts of five
plasmids encoding codon-optimized gp120 genes from primary
HIV-1 isolates: A (92UG037.8), B (92US715.6), Ba-L, Czm
(96ZM651), and E (93TH976.17) in the common vector
pSW3891 as previously described [27]. DNA vaccine plasmids
were grown up in HB101 strain of E. coli, and prepared using a
Plasmid Giga Kit (Qiagen, Valencia, CA). Endotoxin-free DNA
plasmids were prepared using EndoFree Plasmid Mega Kit
(Qiagen). According to Qiagen technical specifications,
EndoFree Plasmid Kits yield DNA plasmids associated with
<0.1 EU/ μg DNA, while standard Plasmid Kits are estimated at
9.3 EU/μg DNA. DNA plasmid expression was confirmed by
transient expression in 293T cells and Western blot.
HIV-1 gp120 Protein/Adjuvant Formulations
The protein component of DP6-001 was composed of equal
parts of five recombinant gp120 proteins homologous to DNA
Serum Cytokine Profiles of Vaccine Adjuvants
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vaccine components. These gp120 proteins were produced in
CHO cell lines by Advanced Bioscience Laboratory, Inc. (ABL)
as previously described [7]. Final protein product consisted of 7
µg/ per gp120 protein at each immunization, in Dulbecco’s
phosphate buffered saline (DPBS) (Gibco, Invitrogen, Grand
Islands, NY). Protein mixes were formulated prior to
immunization with the candidate adjuvants: 5 µg QS-21, 175
µg Al(OH)3 gel (Sigma Aldrich Corp., St. Louis, MO), 25 µg
synthetic MPLA (Avanti Polar Lipids, Inc., Alabaster, AL), or 1.5
ISCO™ Units of ISCOMATRIX™ adjuvant (CSL Limited,
Parkville, Victoria, Australia). 1.5 ISCO™ Units is equivalent to
1.5 µg of ISCOPREP™ saponin and to allow easier
comparison with other adjuvants the µg measurement is used
in this article.
Animal Immunizations
Balb/c (6-8 weeks old, mixed sex) and C57Bl/6 (6-8 weeks
old, mixed sex) mice were obtained from Taconic Farms and
maintained in Department of Animal Medicine animal facility at
University of Massachusetts Medical School, according to an
IACUC-approved protocol. Mice received intramuscular (i.m.)
DNA immunizations of total 120 µg gp120 DNA plasmid at
each immunization, divided between each quadriceps at weeks
0, 2, and 4. Sera were collected following each immunization.
After the third DNA immunization, sera were collected 6 hours
following immunization. Mice received protein boosts of 7 µg/
mouse per gp120 protein for a total protein immunization of 35
µg at each immunization. Protein boosts were formulated with
candidate adjuvants as described above, and administered via
two i.m. injections divided between each quadriceps at weeks 8
and 12. Mice were bled multiple times for serum antibody and
cytokine analysis (Figure 1). Mice were terminated 7 days after
the final protein boost according to an IACUC approved
procedure, at which time sera and spleens were collected.
Enzyme linked immunosorbent assay (ELISA)
gp120-specific antibody responses were assessed by ELISA,
performed as previously described with some modifications
[28]. Briefly, 96-well EIA/RIA microtiter plates (Costar, Corning,
NY) were coated with 5 µg/well ConA diluted in PBS for 1 hr.
Between each step, plates were washed with PBS and 0.1%
Triton X-100 five times using AquaMax2000 automatic plate
washer (Molecular Devices, Sunnyvale, CA). Plates were
coated with 1 µg/ml of the five recombinant gp120 protein mix
used in immunizations. Wells were blocked overnight (4%
whey by weight whey dilution buffer and 5% powdered milk) at
4oC. Plates were incubated with 100 µl of serially diluted mouse
sera in duplicate for 1 hr. Biotinylated anti-mouse IgG (Vector
Figure 1.  Study design and immunization schedule.  C57Bl/6 mice were immunized with three pentavalent DNA primes followed
by two heterologous gp120 protein boost. The pentavalent vaccine mixture of both DNA and protein components consisted of HIV-1
Env from clades A (92UG037.8), B (92US715.6 and Bal), C (96ZM651), and E (93TH976.17). DNA and protein doses indicated are
for a total of five immunogens at each immunization. Four adjuvants were tested individually as part of the protein boost. Time
points of immunizations, and sample collections for different assays were indicated.
doi: 10.1371/journal.pone.0074820.g001
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Laboratories, Burlingame, CA) was added at 1.5 µg/ml for 1 hr.
Horseradish-peroxidase (HRP)-conjugated streptavidin (Vector
Laboratories) at 0.5 µg/ml was added and incubated for 1 hr.
Plates were developed with TMB substrate (Sigma-Aldrich, St.
Louis, MO) for 5 minutes, followed by the addition of 2 N
H2SO4. Optical density (OD) of 450 nm (OD450) minus the
background of plate absorbance at 630 nm, was read on a
Multiskan FC (Thermo Fischer Scientific, Waltham, MA). The
endpoint titer was determined as the highest dilution at which
the OD450 equaled twice the OD450 of negative control wells.
Statistically significant differences between titers were
analyzed using Student’s t test.
For temporal antibody responses, pooled mouse sera
dilutions of 1:250 or 1:500 were prepared for each collection
time point. For mouse IgG isotyping ELISA, standard curve
wells were coated with 0.5 µg/ml IgG2c or IgG1 coating
antibody (Southern Biotech, Birmingham, AL) at 1:3 serial
dilutions from a starting dilution of 1:1000. Biotin-conjugated
IgG2c or IgG1 detection antibody (Southern Biotech) was
applied at 0.5 µg/ml. Plates were washed, developed, and
endpoint titers were determined as described above.
Splenocyte preparation
Spleens were harvested 7 days following the second protein
boost. Spleens were homogenized in complete RPMI media,
with 10% heat-inactivated FBS (HyClone, Logan, UT), and 1%
Penicillin-Streptomycin. Single-cell suspensions were made by
pressing each spleen through a screen, and washing with
media. Red blood cells were lysed with Red Blood Cell Lysis
Buffer (Sigma). Cells were washed, counted, and diluted to a
final concentration of 1x107 cells/ml.
Intracellular cytokine staining
All fluorophore-conjugated antibodies, unless otherwise
noted, were obtained from BD Pharmingen (San Diego, CA).
Splenocytes were cultured in 96-well cell culture round-bottom
plates (Costar) at 1x106 cells per well. Splenocytes were co-
incubated with 2 µg/ml human IL-2, GolgiPlug (BD Biosciences,
San Diego, CA), and peptide. Positive controls were stimulated
with BD Leukocyte Activating Cocktail (BD Pharmingen, San
Diego, CA). Antigen-specific stimulation consisted peptides
8771-8886 from a consensus clade B peptide pool (Cat. No.
9480, NIH AIDS Research & Reference Program,
Germantown, MD) covering the region of gp120, composed of
115 15mer peptides overlapping by 11 amino acids each, at an
individual peptide concentration of 2 µg/ml. Mock-stimulated
splenocytes were treated with media, hIL-2, and GolgiPlug
alone. Splenocytes were incubated at 37oC for 5 hr, after which
cells were washed in 2% FBS/PBS staining buffer. Non-specific
binding was blocked by incubating with 5 µg/ml α-Fcγ R III/II
(2.4 G2) antibody (BD Pharmingen) at 4oC for 10 minutes.
Cells were washed in staining buffer, and then incubated with
LIVE/DEAD Fixable Blue (Invitrogen, Carlsbad, CA). Cells were
washed in staining buffer, and then incubated with anti-CD4-
Alexa700 and anti-CD8-PerCPCy5.5 at 0.4 µg/ml for 20
minutes at 4oC. Cells were washed in staining buffer, and were
then fixed and permeabilized in Cytofix/Cytoperm (BD
Biosciences) in the dark at 4oC for 20 minutes. Cells were
washed in 1X PermWash (BD Biosciences). Cells were stained
with anti-IFNγ-FITC, anti-IL-2-PECy7, and anti-IL-6-PE, diluted
in 1X Permwash, for 30 minutes at 4oC. Cells were washed in
Permwash, and resuspended in staining buffer. Stained
splenocytes were analyzed on an LSRII FACS machine (BD
Biosciences, San Jose, CA), and data was analyzed using
FlowJo software (Treestar, Ashland, OR).
T Cell ELISpot
ELISpot reagents (IL-2, IL-4 IFNγ) were obtained from
Mabtech (Mariemont, OH) or from BD Biosciences (IL-6) (San
Diego, CA). ELISpots were performed according to
manufacturer’s instructions. Pre-coated MSIP PVDF-plates
(Millipore, Billerica, MA) were seeded with splenocytes from
immunized mice (prepared as above) at a 2.5x105 cells/well.
Positive controls were stimulated with 20 ng/ml phorbol 12-
myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO) and
500 ng/ml ionomycin (Sigma-Aldrich). Antigen-specific
stimulation was performed with truncated peptide pools derived
from clade B consensus Env including the V2/V3 pool
(8836-8844) [29] (provided by NIH AIDS Reagent Repository),
at an individual peptide concentration of 2 µg/ml. Mock-
stimulated wells received media only. Plates were incubated
18-20 hr at 37oC in 5% CO2. Positive spots were visualized on
a CTL Imager and counting was performed with ImmunospotTM
software (Cellular Technology Ltd., Shaker Heights, OH)
Luminex
Cytokines and chemokines were quantified in serum
collected from individual mice prior to immunization at week 0,
and 6 hr following each protein boost at weeks 8 and 12, using
a custom Bio-Plex cytokine assay (Bio-Rad, Hercules, CA)
according to manufacturer’s instructions. The panel of
cytokines and chemokines included: IFNγ, IL-1β, IL-2, IL-4,
IL-6, Eotaxin, G-CSF, KC, MIP-1α, MIP-1β, MCP-1, and
RANTES. After collection, serum samples were stored at -80oC
until the conclusion of the study, and all serum samples from
each time point of interest were run in a single Luminex
experiment. Prior to assay, serum samples were diluted 1:4 in
sample diluent. Samples were read on a Bio-Plex 200 system
with Bio-Plex Manager software (Bio-Rad).
Statistical analysis
All data is presented as the mean of individual mice +/-
standard error of the mean (SEM). Statistical analysis was
performed using a Student’s t test, a one-way ANOVA followed
by a Tukey post-test, or a two-way ANOVA followed by a
Bonferonni post-test.
Results
Study Design and Immunization Schedule
Wild type C57Bl/6 and Balb/c mice were immunized with
DP6-001 gp120 vaccines formulated with different adjuvants
based on a dose and schedule from previously completed
clinical studies (Figure 1). Mice were primed i.m. three times
with pentavalent gp120 DNA plasmids at weeks 0, 2, and 4 and
Serum Cytokine Profiles of Vaccine Adjuvants
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boosted with two matched pentavalent gp120 protein boosts,
formulated with either QS-21, Al(OH)3, MPL, or
ISCOMATRIX™ adjuvant, at weeks 8 and 12. For an initial
study examining the impact of two different DNA plasmid
preparation methods, controls groups were immunized with
only three pentavalent gp120 DNA immunizations, and
received saline immunization in lieu of protein boosts.
Differences in serum cytokines following immunization
with gp120-expressing DNA plasmids in different
preparations
In previous small animal studies of the DP6-001 DNA prime-
protein boost formulation, gp120 DNA plasmid components
were prepared using a regular plasmid kit as described above.
Prior to the analysis of serum cytokines in response to the
DP6-001 and candidate adjuvants, we aimed to rule out the
potential contribution of residual endotoxin content in DNA
plasmid preparations to the cytokine profiles observed. Mice
received either three DNA immunizations followed by two
saline boosts, or the full course of the DP6-001 DNA prime-
protein boost vaccine regimen. DNA primes were prepared by
either regular DNA plasmid kit or EndoFree DNA plasmid kit
(referred to as EF DP6-001), as described above in Materials
and Methods. Protein boosts were formulated with the QS-21
adjuvant, as with our previous studies of DP6-001
[5–7,27,30,31]. To characterize the systemic serum cytokines
produced following adjuvanted protein immunization, in
comparison to pre-immunized serum, we employed a multiplex
cytokine array consisting of a panel of 12 cytokines including
Th1 cytokines [Interleukin (IL)-2 and IFNγ], Th2 cytokines
[IL-4], and pro-inflammatory cytokines [IL-1β, IL-6, RANTES
(CCL5)]. In addition, we included cytokines and chemokines
associated with activation and chemoattraction of monocytes,
macrophages, NK cells, and granulocytes [MCP-1 (CCL2),
MIP-1α (CCL3), MIP-1β (CCL4), G-CSF], neutrophils [KC
(CXCL1)] and eosinophils [Eotaxin].
Overall, the different plasmid preparation methods employed
did not substantially impact the levels of cytokine responses
elicited at time points during the protein-adjuvant boost phase
when the serum cytokine profiles will be measured. Eotaxin
and MIP-1α were the only two cytokines moderately elevated in
serum in mice immunized with regular DNA prep following the
first protein boost as compared to EF DP6-001 but the
difference dropped after the 2nd protein boost (data not shown).
Several of the analyzed cytokines detected in the serum clearly
demonstrate the increased immune response associated with
DNA prime-protein boost, as compared to immunization with
DNA alone, seen in the comparison of serum cytokine levels 6
hours after the third DNA prime with the levels in serum 6
hours after each protein boost. Regardless of the method of
DNA vaccine preparation, the serum levels of IL-2, IL-6,
MCP-1, G-CSF, and KC were increased at 6 hours post-protein
boost as compared time points 6 hours following the final DNA
prime immunization (Figure 2).
During DNA priming immunizations, the serum levels of IL-2
(Figure 2A) and MCP-1 (Figure 2B) were low overall in mice
primed with either DNA plasmid preparation. We observed a
trend towards increased serum levels of IL-6 (Figure 2C), KC
(Figure 2D), and G-CSF (Figure 2E) during DNA priming steps
in mice immunized with regular DNA preparations as compared
to EF preparations. However, these differences were not
significant. Rather, serum levels of these cytokines were
significantly boosted above DNA priming levels by protein
boosts, while serum cytokine levels in mice that did not receive
protein boosting dropped trended down towards background
levels (Figure 2C–E). These results suggested that our future
studies of adjuvanted protein-associated serum cytokine
profiles in the context of DNA prime-protein boost should focus
on time points 6 hours after protein-adjuvant boosting.
Importantly, we did not observe any significant differences in
these serum cytokines between regular and EF DNA
preparations at time points 6 hours after protein boost. This
indicates the minimal impact of potential endotoxin content
associated with different DNA plasmid preparations on the
serum cytokines we measured at our time points of interest.
Remaining cytokines were either not above the background
levels during both after DNA and protein immunizations (IFNγ
and IL-4), or were at low concentration only after DNA priming
phase but not after protein immunization (MIP-1β and
RANTES) (data not shown).
Effect of DNA prep in gp120-encoding DNA plasmid on
DP6-001 vaccine-induced Env-specific IgG response
In addition to examining nonspecific serum cytokine
responses, we aimed to rule out the potential impact of gp120
DNA plasmid preparations on the Env-specific IgG antibody
response observed in our adjuvant studies. Sera collected from
the immunized mice 7 days following the final protein boost
was used to determine the Env-specific IgG endpoint titer by
ELISA (Figure 3). As expected, mice that received the full
DP6-001 with adjuvanted protein boost demonstrated
significantly higher IgG titers than mice that received DNA
priming only, regardless of the method of g120 DNA plasmid
preparation.
Induction of Env-specific T cell responses by DP6-001
vaccine
Once we established the regular DNA prep was qualified for
use in the current studies, T cell responses following
immunization with DP6-001 with various candidate adjuvants
were characterized in C57Bl/6 mouse splenocytes. ELISpot
analysis was conducted to examine DP6-001 vaccine-induced
production of Th1 and Th2 responses in the splenocytes of
immunized mice, in response to a peptide pool (labeled ‘PP’)
representing clade B Env consensus sequence [29]. Mice that
received DP6-001 formulated with QS-21 most strongly
produced an Env-specific IFNγ response, with much lower
levels observed in mice immunized with protein formulated with
Al(OH)3, MPLA, and ISCOMATRIX™ adjuvant (Figure 4A). All
mice receiving adjuvanted protein formulations demonstrated a
positive IL-2 response to peptides (Figure 4B) and minimal
induction of IL-4 (Figure 4C) with no differences between
groups. Baseline levels of Th2 cytokines IL-4 and IL-6 were
notably elevated (Figure 4C, D). Mice receiving protein
formulated with QS-21 demonstrated a positive but not
significant induction of IL-6 over background, while those
Serum Cytokine Profiles of Vaccine Adjuvants
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receiving protein formulated with all other adjuvants showed
minimal induction of IL-6 (Figure 4D).
Intracellular cytokine staining (ICS) was also conducted to
evaluate the functionality of vaccine-specific T cells by the
production of Th1 and Th2 cytokines (IFNγ, IL-2 and IL-6) in
response to a pool of overlapping peptides representing the
clade B consensus Env sequence (Figure S1). No significant
difference in CD4+ T cell cytokine induction was observed
between adjuvanted protein groups. Similar to ELISpot results,
mice immunized with protein formulated with QS-21 showed
significant induction of Env-specific IFNγ (Figure S1A) and IL-6
(Figure S1C) by CD4+ T cells, and a marginally positive IL-2
(Figure S1B) response by CD4+ T cells. While there was a
trend of positive Env-specific IFNγ responses by CD8+ T cells
(Figure S1D), responses were not significantly induced above
background, nor were there any significant differences between
the different adjuvants. This result is not surprising as protein
vaccines are not known for the induction of CD8+ T cell
responses and DP6-001 vaccine was mainly designed for the
induction of antibody responses.
Figure 2.  Temporal serum cytokine levels in mice immunized with endotoxin-free (EF) DNA prime compared to regular
DNA plasmid preparation.  Pentavalent gp120 DNA priming components were produced with either a regular or an EF DNA
plasmid preparation kit. C57Bl/6 wild type mice were immunized with either three gp120 DNA primes and two “mock” saline boosts
(‘DNA’ or ‘EF DNA’), or with three gp120 DNA primes and two gp120 protein boosts adjuvanted by QS-21 (‘D+P-QS-21’ or ‘EF D+P-
QS-21’). Serum cytokines were quantified with a 12-plex Luminex panel in sera collected pre-immunization (‘Prebleed’), and at 6
hours after each of three DNA primes (‘D1,’ ‘D2,’ and ‘D3’) and two protein boost (‘P1,’ ‘P2’) immunizations. Shown are serum levels
of (A) IL-2, (B) MCP-1, (C) IL-6, (D) G-CSF, and (E) KC. Statistical analysis was performed with a Student’s t test (*: p < 0.05, **: p <
0.01, ***: p < 0.001).
doi: 10.1371/journal.pone.0074820.g002
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Figure 3.  Endpoint gp120-specific IgG titer in C57Bl/6 mice immunized with endotoxin-free DNA prime versus regular DNA
plasmid preparation.  Total gp120-specific IgG was measured by ELISA in sera collected 7 days after the second protein boost, in
week 13. Statistical analysis performed by one-way ANOVA and Tukey post-test (*: p<0.05).
doi: 10.1371/journal.pone.0074820.g003
Figure 4.  Env-specific cellular immune responses in splenocytes from mice immunized with DP6-001 and candidate
adjuvants.  Spleens were harvested from immunized C57Bl/6 wild type mice at termination 7 days after the final protein boost.
Cells were cultured for 18 hours either receiving the stimulation of a truncated HIV-1 gp120 Clade B peptide pool (‘PP’) or media
(‘mock’). Cytokine spot-forming units (SFU) per million splenocytes were visualized with a CTL Imager and analyzed with
Immunospot™ software. Splenocyte production of gp120-specific Th1 cytokines (A) IFNγ and (B) IL-2, and gp120- specific Th2
cytokines (C) IL-4 and (D) IL-6 were measured. Statistical analysis of peptide stimulation over mock stimulation was calculated by
Student’s t-test. Significant values (*: p < 0.05) are represented above error bars. Statistical differences in peptide stimulation
between adjuvant groups were calculated by a Two-way ANOVA and Bonferroni post-test (*: p < 0.05, **: p < 0.01, ***: p < 0.001)
(IMX = ISCOMATRIX™ adjuvant)..
doi: 10.1371/journal.pone.0074820.g004
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Eliciting Env-specific IgG antibody response using
DP6-001 DNA prime and protein boost formulated with
candidate adjuvants
In immunogenicity studies of DP6-001 in small animals and
clinical volunteers, we reported the robust induction of vaccine-
specific antibody response following immunization with the
polyvalent Env DNA prime-protein boost formulation DP6-001
[5–7,27,30,31]. In our previous Phase I clinical study, DP6-001
protein boosts have been formulated with the saponin adjuvant,
QS-21. In order to investigate the immunogenicity of alternative
candidate adjuvants, particularly in comparison to QS-21, we
immunized two strains of wild type mice with the pentavalent
gp120 DNA prime-protein boost regimen employed in a phase I
clinical trial [5–7]. Balb/c and C57Bl/6 mice were immunized
with three DNA primes, followed by two protein boosts
formulated with QS-21, Al(OH)3, MPLA, or ISCOMATRIX™
adjuvant according to the study design outlined in Figure 1.
Sera were collected every two weeks after DNA immunization,
and six hours post-protein boosts. Sera collected from mice
seven days following the second protein boost were used to
ascertain the endpoint titer of Env-specific IgG responses. For
antibody responses, there is limited difference between Balb/c
C57Bl/6 mice, and only data from C57Bl/6 wild type mice are
presented.
Immunization with DP6-001 produced comparably robust
gp120-specific IgG responses following the final protein boost,
independent of the adjuvant used. Env-specific IgG levels were
detectable following the third DNA immunization, and were
significantly boosted by the first protein immunization. Levels of
specific IgG dropped four weeks following the first protein
boost, but were subsequently boosted by the second protein
immunization (Figure 5A). Endpoint titer analysis showed that
gp120-specific IgG levels were comparable in mice receiving
formulations containing QS-21 or MPLA. IgG titers were
significantly lower in mice immunized with formulations
containing ISCOMATRIX™ adjuvant as compared to
formulations containing MPLA and lower again in mice
receiving formulations containing Al(OH)3 (Figure 5B).
In C57Bl/6 mice, sera collected 7 days after the final protein
immunization was used to characterize the IgG isotype profiles
of formulations with the candidate adjuvants. HIV-1 gp120-
specific IgG1 titers were comparable between mice that
received formulations containing QS-21, Al(OH)3, or MPLA
adjuvants (Figure 5C). In comparison, IgG1 titers were slightly,
but not significantly lower, in mice that received formulations
containing ISCOMATRIX™ adjuvant. On the other hand,
gp120-specific IgG2c titers were higher in mice immunized with
formulations containing QS-21 and MPLA followed by
formulations containing ISCOMATRIX™ adjuvant in
comparison to mice that received formulations containing
Al(OH)3 (Figure 5D). A ratio of the endpoint titers of Env-
specific IgG2c, a correlate of Th1 responses, and IgG1, a
correlate of Th2 responses, were used to demonstrate the Th1
vs. Th2 responses associated with each adjuvant (Figure 5D).
Mice immunized with formulations containing Al(OH)3
demonstrated a low IgG2c/IgG1 ratio, and therefore
predominantly Th2 response. In contrast, mice immunized with
formulations containing MPLA or QS-21, and to a greater
extent, ISCOMATRIX™ adjuvant, demonstrated a higher
IgG2c/IgG1 ratio, indicating strong Th1 responses.
Induction of unique serum cytokine profiles following
protein boost with candidate adjuvants
Sera were collected throughout the DP6-001 immunization
schedule in the current study, including time points prior to
immunization at week 0, and also 6 hours following each
protein-adjuvant boost at weeks 8 and 12. In order to
characterize the serum cytokines produced following protein-
adjuvant immunization, in comparison to pre-immunized serum,
we employed a 12-plex cytokine array described above. By
examining this panel of non-antigen specific, systemic cytokine
responses in immunized mice 6 hours after each protein-
adjuvant boost, our objective was to identify a unique profile of
markers for each candidate adjuvant in the context of our
prime-boost HIV vaccine. In addition, we will also identify
cytokines and chemokines that are broadly induced by
formulations containing the candidate adjuvants.
Animals immunized with DP6-001 including a boost of gp120
protein formulated with QS-21 demonstrated a unique serum
cytokine profile, consisting of the Th1 cytokine IFNγ and the
Th2 cytokine IL-4. Immunization with formulations containing
QS21 was also associated with increased levels of the pro-
inflammatory marker IL-1β, and the monocyte chemoattractant
MIP-1β (Figure 6A). While levels of these four cytokines were
relatively low in all adjuvant groups 6 hours after the first
protein boost, they were clearly elevated in animals immunized
with formulations containing QS21 following the second protein
boost. Animals immunized with formulations containing QS-21
also demonstrated significantly higher IFNγ, IL-4, and IL-1β as
compared to animals immunized with formulations containing
Al(OH)3 or MPLA. Levels of MIP-1β, a chemoattractant for
natural killer (NK) cells and monocytes, were significantly
higher than in Al(OH)3-immunized animals. While mice
immunized with formulations containing QS-21 showed
significantly higher levels of IL-4 after the second protein boost
in comparison to mice immunized with formulations containing
ISCOMATRIX™ adjuvant, no significant differences were
observed in other signature cytokines at this time point (Figure
6A).
Mice immunized with DP6-001 formulated with MPLA
demonstrated significantly higher levels of the multifunctional
and broadly acting chemokine RANTES in serum 6 hours after
the first protein boost, as compared to other protein-adjuvant
formulations (Figure 6B). Following the second protein-
adjuvant boost, serum levels of RANTES were reduced in all
groups, though in mice immunized with formulations containing
MPLA the levels remained elevated compared to other
formulations. In addition, levels of G-CSF were significantly
increased in mice immunized with formulations containing
MPLA following the first protein boost in comparison to mice
immunized with formulations containing QS-21 or Al(OH)3
(Figure 6B).
Similarly, G-CSF was significantly increased at this time
point in mice immunized with formulations containing
ISCOMATRIX™ adjuvant in comparison to mice immunized
with formulations containing QS-21 or Al(OH)3 (Figure 6B). G-
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CSF, which induces proliferation and differentiation of
granulocytes, was characteristic of formulations containing
either MPLA or ISCOMATRIX™ adjuvant in the context of the
DP6-001 vaccine. In addition, animals receiving DP6-001
vaccine formulated with ISCOMATRIX™ adjuvant exhibited a
unique profile of pro-inflammatory markers. The Th1 cytokine
IL-2 was significantly increased following the first protein boost
in mice immunized with formulations containing
ISCOMATRIX™ adjuvant in comparison to formulations
containing QS-21 or Al(OH)3. In addition, chemoattractants for
eosinophils (Eotaxin), or monocytes and DCs (MCP-1), were
also characteristic of formulations containing ISCOMATRIX™
adjuvant (Figure 6C). After the first protein boost, serum levels
of MCP-1 in mice immunized with formulations containing
QS-21 or Al(OH)3 were significantly lower compared to
formulations containing ISCOMATRIX™ adjuvant, while levels
Figure 5.  HIV-1 gp120-specific IgG response in C57Bl/6 wild type mice immunized with DP6-001 vaccine with different
adjuvants.  Total gp120-specific IgG was measured by ELISA in sera collected 7 days after final protein boost, in week 13. Protein
boosts were formulated with QS-21 (red), Al(OH)3 (green), MPLA (blue), or ISCOMATRIX™ adjuvant (IMX) (purple). Naïve mice
(black) received ‘mock’ saline injections in lieu of immunization. (A) Temporal gp120-specific IgG response was determined by
ELISA using pooled sera samples from each group collected at two-week intervals. (B) gp120-specific endpoint IgG titer in was
determined by ELISA using individual serum samples collected in week 13. (C) Endpoint IgG isotype profiles were determined by
ELISA using individual serum samples collected in week 13. (D) Th1/Th2 ratio of IgG isotype responses was determined by
comparing IgG2c/IgG1 ratio. Statistical significance was determined by one-way ANOVA and Tukey post-test (*: p < .05, **: p < .01,
***: p < .001).
doi: 10.1371/journal.pone.0074820.g005
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Figure 6.  Serum cytokine concentration in mice vaccinated with DP6-001 and candidate adjuvants.  C57Bl/6 wild type mice
were immunized with DP6-001 DNA prime-protein boost (‘D+P’), with each protein boost formulated with QS-21 (D+P-QS-21),
Al(OH)3 (D+P–Al(OH)3), MPLA (D+P-MPLA) or ISCOMATRIX™ adjuvant (D+P-IMX). Naïve mice received saline injections in lieu of
immunization. Sera were collected pre-immunization and 6 hours following the first (P1) and second (P2) protein-adjuvant boosts.
Cytokines were quantified in the serum of individual mice at a 1:4 dilution using a custom 12-plex Luminex panel. (A) QS-21
cytokine profile. (B) MPLA cytokine profile. (C) ISCOMATRIX™ adjuvant (IMX) cytokine profile. (D) Serum cytokines elevated
following protein boost with formulations containing all candidate adjuvants. Significance over background is represented above
error bars. Bracketed lines represent differences between adjuvant groups. Statistical significance was determined with a One-way
ANOVA and Tukey post-test (*: p < .05, **: p < .01, ***: p < .001).
doi: 10.1371/journal.pone.0074820.g006
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in mice immunized with formulations containing MPLA were
comparable. However, serum levels of Eotaxin were
significantly increased in mice immunized with formulations
containing ISCOMATRIX™ adjuvant in comparison to mice
immunized with all other adjuvanted formulations.
Several serum cytokines and chemokines in our panel were
shared among different candidate adjuvants in the context of
HIV-1 gp120 DNA prime-protein boost vaccine. The neutrophil
chemoattractant KC was strongly elevated in serum following
protein boosts in mice immunized with DP6-001 formulated
with QS-21, MPLA and ISCOMATRIX™ adjuvant, as compared
to naïve and mice immunized with formulations containing
Al(OH)3. There was no significant difference between these
three adjuvanted formulations, although mice immunized with
formulations containing ISCOMATRIX™ adjuvant
demonstrated significantly higher levels of KC after the second
protein boost as compared to formulations containing Al(OH)3
(Figure 6D).
IL-6, which may act as both a pro- and anti-inflammatory
cytokine in response to a variety of stimuli, was strongly
induced following protein boost in with formulations containing
QS-21, MPLA, and ISCOMATRIX™ adjuvant, while levels in
the mice immunized with formulations containing Al(OH)3 were
very low. After the first protein boost, levels of IL-6 in mice
immunized with formulations containing QS-21 and
ISCOMATRIX™ adjuvant were both elevated comparably.
Interestingly, in animals receiving protein boost formulated with
MPLA, after one protein boost levels of IL-6 were significantly
lower than those induced by formulations containing
ISCOMATRIX™ adjuvant. By the second protein boost,
however, levels of IL-6 induced by the formulations containing
MPLA had risen to be comparable to initial levels seen with
formulations containing ISCOMATRIX™ adjuvant, while the
levels of IL-6 in mice immunized with formulations containing
ISCOMATRIX™ adjuvant had notably fallen (Figure 6D).
Table 1 summarizes the serum cytokine profiles associated
with each candidate adjuvant in the context of DP6-001, by
comparing the fold-increase over background for each
adjuvant.
Induction of serum cytokines by a protein-adjuvant
vaccine in the absence of DNA prime
In order to define the effect of DNA priming on the protein
and adjuvant serum cytokine profiles, additional study was
performed in C57Bl/6 wild type mice that received only two
DP6-001 protein boosts formulated with candidate adjuvants
without DNA prime. Mice were immunized at weeks 0 and 4,
and sera were collected for cytokine analysis at 6 hours after
each protein boost. Serum cytokines were quantified in
immunized mice in comparison to naïve mice using the 12-plex
array described above.
Generally, serum cytokine levels associated with a protein-
only vaccine were reduced in comparison to those observed in
mice immunized with the complete DP6-001 DNA prime-protein
boost regimen. Protein-only vaccine formulated with QS-21
results in low to background levels of Th1 and Th2 cytokines,
including the previously observed QS-21-associated signature
cytokines, IFNγ and IL-4 (Figure 7A-B). The inflammatory
cytokine IL-1β and the chemokine MIP-1β, associated with
QS-21 in the context of DP6-001 prime-boost vaccine, were
substantially reduced after immunization with a protein-only
vaccine (Figure 7A-B). Similarly, protein vaccine formulated
with QS-21 demonstrated moderate reductions in the
chemokines G-CSF, MCP-1, MIP-1α, and RANTES (Figure 7A-
B). While DP6-001 prime-boost vaccine formulated with
Al(OH)3 produced overall low, unimpressive cytokine profiles
(Figure 7C), we observed that protein-only immunization with
formulations containing Al(OH)3 also demonstrated even lower
or negligible levels of Th1/Th2 cytokines, inflammatory
cytokines, and chemokines (Figure 7D).
Similar studies with protein alone vaccination were
conducted with formulations containing MPLA and
ISCOMATRIX™ adjuvant, but also included groups that
received three empty DNA vector as the prime followed with
protein boost (Figure 7). In the context of a prime-boost
vaccine, formulations containing MPLA were primarily
characterized by potent induction of G-CSF and RANTES
(Figure 7E). Interestingly, while Th1/Th2 cytokines and other
chemokines are notably reduced following a protein-only
vaccine formulated with MPLA, the MPLA formulation-
associated signature chemokines G-CSF and RANTES, as well
as MCP-1 and KC, are minimally changed in the absence of
DNA priming (Figure 7F). Vector-primed mice immunized with
protein-MPLA demonstrated reduced cytokines and
chemokines (Figure 7G) in comparison to mice immunized with
the complete DP6-001 regimen (Figure 7E).
Of the signature cytokines associated with formulations
containing ISCOMATRIX™ adjuvant in the context of the
DP6-001 prime-boost vaccine, such as IL-2, Eotaxin, G-CSF
and MCP-1 (Figure 7H), IL-2, Eotaxin, and MCP-1 were
substantially reduced in mice immunized with protein-only
Table 1. Trends in serum cytokine and chemokine induction
over background following first and second protein-adjuvant
boosts.
 D+P+QS-21 D+P+Al(OH)3 D+P+MPLA D+P+IMX
 P1 P2 P1 P2 P1 P2 P1 P2
IFNγ + ++ + - + + + +
IL-2 ++ ++ ++ + ++ + +++ ++
IL-4 - + - - - - - -
IL-6 ++ + + - + ++ ++ +
IL-1β - + - - - - - -
Eotaxin + + + - ++ - +++ +
KC + + + - + + + +
G-CSF ++ + + + +++ ++ +++ ++
RANTES + - + - ++ + + -
MCP-1 + + + - ++ ++ +++ +++
MIP-1α ++ + ++ + ++ + + +
MIP-1β + + - - + + + +
Profiles Were Determined by Calculating the Fold Increase of Individual C57BL/6
Wild Type Mice in Each Group over Their Respective Pre-Immunization Cytokine
Levels. Data Is Representative of Cytokine Data Shown In Figure 6. <2-Fold
Increase: -. 2-10-Fold Increase: +. 10-30-Fold Increase: ++. >30-Fold Increase: ++
+. (IMX = ISCOMATRIX™ Adjuvant)
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vaccine containing ISCOMATRIX™ adjuvant (Figure 7I).
Though still above pre-immunization levels, serum levels of G-
CSF were reduced in the absence of a DNA prime (Figure 7I).
Control mice immunized with three empty vector DNA primes
followed by DP6-001 protein boosts formulated with
ISCOMATRIX™ adjuvant, however, demonstrated low or
negative levels of all of the serum cytokine and chemokines
analyzed (Figure 7J).
In summary, from our analysis of serum cytokines associated
with candidate adjuvants formulated with the DP6-001 prime-
boost vaccine, several markers, IL-6, KC, and MIP-1β, were
identified that were comparably induced following protein
boosting with formulations containing either QS-21, MPLA, or
ISCOMATRIX™ adjuvant. Consistent with the trend of reduced
cytokines associated with the absence of DNA priming, both
IL-6 and MIP-1β were reduced or negative in comparison to
Figure 7.  Compiled serum cytokine panels following the first protein boost in mice vaccinated with Env protein formulated
with QS21 or Al(OH)3.  C57Bl/6 wild type mice vaccinated with protein-only vaccine (‘P’) received immunizations at weeks 0 and 4
with the DP6-001 protein. Cytokines were quantified in serum from individual mice collected 6 hours following protein boost by a 12-
plex Luminex array. Shown are serum cytokine levels 6 hours after the first protein-adjuvant boost. Mice were immunized with either
DP6-001 prime-boost vaccine and adjuvants, a protein-only vaccine with adjuvants, or a vector-primed protein boost with adjuvants.
(A) D+P-QS-21. (B) 2P-QS-21. (C) DP6-001-Al(OH)3. (D) 2P–Al(OH)3. (E) DP6-001-MPLA. (F) 2P-MPLA. (G) V+P-MPLA. (H) D+P-
IMX. (I) 2P-IMX. (J) V+P-IMX.
doi: 10.1371/journal.pone.0074820.g007
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DNA primed animals. A notable exception to this trend was the
neutrophilic chemoattractant KC, which remained at
comparable levels regardless of vaccine regimen (Figure 7).
The inclusion of protein-only vaccines and empty vector DNA
prime controls allows us to confirm that the cytokine and
chemokine profiles associated with our candidate adjuvants are
unique to the context of a DNA prime-protein boost vaccine
strategy, and confirmed the concept that the improved
immunogenicity based on serum cytokines was due to the
inclusion of DNA priming steps.
Discussion
In recent years, the heterologous prime-boost vaccination
strategy has demonstrated considerable advantages over the
classical vaccine strategies based on homologous prime-boost
strategies. Results from RV144 clinical trial of viral vector prime
and recombinant gp120 protein boost demonstrated
unprecedented partial protection against the transmission of
HIV-1 [1–4]. Similarly, we have previously reported that the
DP6-001 vaccine formulation, consisting of a DNA prime and
protein boost, was highly immunogenic in both preclinical and
clinical studies [5–7,32]. A Phase I clinical trial of DP6-001
vaccine showed the generation of balanced Env-specific T cell
and high titer Env-specific antibody responses including
broadly neutralizing antibodies in study vaccinees [7].
In both of the above studies, the Env protein boost is now
recognized as a critical component. However, the roles of
adjuvant in such a protein boost immunization remains unclear.
Protein vaccines are formulated with adjuvants with the goal of
promoting and harnessing the innate non-antigen specific, pro-
inflammatory response, and ultimately enhancing the antigen-
specific adaptive immune response. This strategy is not without
the risk of adverse effects. Out of candidate adjuvants in the
current study, only Al(OH)3 and MPLA are components in
licensed vaccines in the United States. Even well established
and tolerable vaccine adjuvants such as Al(OH)3 must be
thoroughly evaluated for both efficacy and safety in the context
of new vaccine formulations before being approved for clinical
use. Vaccine antigen, dosing, route of administration, and
schedule may all impact the immunogenic profile as well as the
reactogenicity of a given adjuvant. In addition, adjuvants must
be selected with the pathogen-specific requirements of
protection in mind. While sterilizing immunity against HIV-1
infection requires a strong humoral response including
neutralizing antibodies, lessons from preclinical studies have
shown that CD8+ and CD4+ T cell responses are important in
facilitating both the humoral and cell-mediated immunity
induced by an HIV-1 vaccine.
In the current study, three well-studied adjuvants, QS-21,
MPLA, and ISCOMATRIX™ adjuvant, in addition to the widely
used Al(OH)3 adjuvant as a control, all demonstrated
comparable immunogenicity in the context of the DP6-001 DNA
prime-protein boost in a mouse model. With the exception of
Al(OH)3, the other three potent adjuvants each strongly induced
a vaccine-specific antibody response. While the QS-21
adjuvant was associated with the strongest induction of Env-
specific CD4+ T cell responses by intracellular cytokine staining
and ELISpot assay, there were no significant differences in
Env-specific Th1 and Th2 responses between the adjuvants
evaluated as determined by ICS. Env-specific T cell ELISpot
results showed that formulations containing QS-21 induced
significantly greater Th1 responses as compared to other
adjuvants. Formulations containing MPLA and ISCOMATRIX™
adjuvant induced positive specific Th1 responses to a lesser
extent than QS-21. In contrast, all adjuvant formulations could
elicit comparably weak Env-specific Th2 responses.
While antigen specific responses were similar for
formulations containing each of the adjuvants included in the
current study, the serum cytokine profiles were quite different.
Multiplex arrays for nonspecific serum cytokines proved an
invaluable tool in detecting differences in the non-Env specific
innate responses to the DP6-001 vaccine and candidate
adjuvants. In the context of the DP6-001 prime-boost vaccine,
the candidate adjuvants were easily distinguished by these
cytokine profiles and chemoattractants indicative of differential
immune cell recruitment. The local and systemic inflammatory
environment induced by an adjuvant formulated with vaccine
requires a delicate balancing act. Early resident and recruited
innate immune cells release of a complex milieu of cytokines
and chemoattractants that together influence subsequent
waves of immune cell infiltrates, and thus enhance antigen
uptake and presentation [33]. Ultimately, this microenvironment
shapes the antigen-specific adaptive immune response,
directing a Th1 or Th2 CD4+ T cell bias and enhancing B cell
function and antibody production. However, overstimulation of
a pro-inflammatory response may result in undesirable local
and systemic symptoms, including hypersensitivity reactions,
fever and myalgia.
The multifunctional cytokine IL-6 is a central player in
inflammation. Along with IL-1β, IL-6 promotes the acute phase
response and fever [34]. IL-6 also mediates neutrophilic
inflammation and the shift from innate acute inflammation to
chronic inflammation and adaptive immunity [35–38]. In the
current study, 6 hours following protein boost, we observed that
IL-6 was universally induced to comparable levels by
formulations containing each candidate adjuvant. This pattern
was also observed for the neutrophil chemoattractant, KC.
These serum cytokine levels associated with formulations
containing the control adjuvant, Al(OH)3, were typically low
compared to all other groups. MIP-1α, which, like MIP-1β, is
produced by macrophages to promote neutrophilic
inflammation and immune cell recruitment [39], was produced
comparably by all adjuvanted formulations including those with
Al(OH)3, but at levels not significantly elevated above
background. These cytokines characteristic of DP6-001 DNA
prime-protein boost with all adjuvants reflects an early, acute
inflammatory response to immunization, likely predominated by
neutrophils.
In the current study, formulations containing QS-21 were
associated with the Th1 cytokine IFNγ and the Th2 cytokine
IL-4, supporting our findings of mixed Env-specific Th1/Th2 T
cell responses and IgG isotyping, as well as previous reports of
Quillaia saponin fractions [40]. Elevated serum MIP-1β was
characteristic of only formulations containing QS-21. IL-1β,
which plays a major role in the acute phase response and fever
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[34], as well as neutrophilic inflammation [39,41], was also
strongly associated with formulations containing QS-21. It may
be a point of interest that these characteristic cytokines were
most strongly observed following the second protein boost,
rather than following the first protein boost, as was the pattern
for other adjuvants. This may be suggestive of a progressive
inflammatory response with subsequent immunizations.
By comparison, the more clinically tolerable saponin
formulation ISCOMATRIX™ adjuvant was characterized by
strong IL-2, which is supportive of an expected Th1 and CD8+ T
cell response. Elevated systemic IL-6 as well as Eotaxin, a
chemoattractant for eosinophils, are indicative of a Th2
response, supporting the reported mixed Th1/Th2 profile of
ISCOMATRIX™ vaccines [12,13,15,16,42,43]. Granulocyte
factor G-CSF and MCP-1, which recruits monocytes and
macrophages subsequent to early neutrophil infiltration [44],
were also associated with the protein boost containing
ISCOMATRIX™ adjuvant. The distinct cytokine and chemokine
pattern observed here with DP6-001/ISCOMATRIX™ adjuvant
consists of Th1 and Th2 cytokines as well as chemoattractants
indicative of the recruitment of monocytes, macrophages, NK
cells, and granulocytes. This profile supports a serum cytokine
profile recently reported by Wilson et al. 6 hours following
subcutaneous administration of ISCOMATRIX™ adjuvant
without antigen [45]. Our profile of DP6-001/ISCOMATRIX™
adjuvant is consistent with a profile of serum cytokines and
immune cell infiltration at draining lymph nodes described by
Duewell et al., consisting of B and T cells, DCs, NK cells, and
granulocytes, in mice subcutaneously immunized with OVA
antigen and ISCOMATRIX™ adjuvant [46].
DP6-001 formulated with MPLA demonstrated high serum
levels of granulocyte factor G-CSF, in addition to elevated
serum RANTES, a T cell-produced chemoattractant for
eosinophils, T cells, and NK cells. The serum cytokine profile of
MPLA observed in the context of the DP6-001 Env DNA prime-
protein boost may support previous evaluations of MPLA
formulations in a mouse model. Mata-Haro et al. previously
reported that in the hours following injection, MPLA formulated
with OVA antigen was correlated with serum G-CSF and
MCP-1, and low but positive RANTES, as compared to LPS.
MyD88-associated IL-6 and MIP-1α were weakly positive, while
IFNγ and IL-1β were minimal [22].
We have described here a complex picture of the differential
immune responses elicited by each candidate adjuvant in the
context of a novel heterologous prime-boost vaccine, with the
goal of identifying correlates of immunogenicity and markers of
reactogenicity that may aid in the selection of an adjuvant for
future optimized vaccine formulations. While the
immunogenicity of the formulation containing our previously
employed adjuvant QS-21 was comparable to formulations with
our other candidate adjuvants, we may be able to correlate a
unique systemic inflammatory response associated with
QS-21. Formulations with all three potent adjuvants, with the
exception of Al(OH)3, demonstrated comparable serum levels
of IL-6 and KC, and low but positive levels of MIP-1α. Beyond
this, the additional pro-inflammatory environment of serum
IL-1β and MIP-1β associated specifically with QS-21 may
contribute to reported adverse events. The predominance of
markers for acute inflammation and fever, as well as products
and mediators of neutrophilic inflammation, is of particular
interest given the nature of a previously reported vasculitis
associated with DP6-001 and QS-21 [6]. Leukocytoclastic
vasculitis is due to the toxic effect of neutrophilic degranulation
products on the endothelial cells of small vasculature [47].
In contrast to QS-21, formulations containing MPLA and
ISCOMATRIX™ adjuvant likely demonstrate potentially milder
reactogenic profiles. Both MPLA and ISCOMATRIX™ adjuvant
are largely characterized by broadly acting chemoattractants
recruiting a varied population of immune cells, including
granulocytes, NK cells, monocytes, DCs, and macrophages.
However, formulations containing either of these adjuvants
demonstrate notably lower levels of additional inflammatory
cytokines and chemokines such as IL-1β and MIP-1β in
comparison to QS-21.
In the process of evaluating different adjuvants with the
DP6-001 formulation, we observed that serum cytokine
responses demonstrate unique kinetics in a prime-boost
vaccine regimen. The optimal time to detect high level cytokine
responses was at 6 hours after the protein boost, while early
studies demonstrated low to negative responses at the end of
DNA priming immunization. Repeated boost with protein-
adjuvant vaccines actually led to a reduced cytokine response
following subsequent protein boosts, except with the use of
QS-21.
In the current study, we performed several control
immunizations to confirm the correlation of our unique adjuvant
serum cytokine profiles to their use in the context of a unique
DNA prime-protein boost vaccine strategy. In animals
immunized with a protein-only vaccine formulated with either
QS-21, Al(OH)3, MPLA, or ISCOMATRIX™ adjuvant, serum
cytokine and chemokine panels were largely reduced in
comparison to those in DNA-primed animals. A similar trend
was observed in animals that received an empty vector DNA
prime and protein boost formulated with our candidate
adjuvants. These serum cytokine profiles from protein-only or
empty vector primed vaccine formulations suggest that the
serum cytokine and chemokine profiles we have defined for
QS-21, MPLA, and ISCOMATRIX™ adjuvant are unique to the
context of a DNA prime-protein boost vaccine strategy.
Furthermore, the poor serum cytokine response induced by
empty vector DNA priming in comparison to DP6-001 DNA
priming suggests that the antigen itself encoded in the DNA
prime plays an important role in the response induced by
subsequent boosting with protein antigen. Certainly DNA
plasmids themselves may activate innate nucleic acid sensing
pathways in a non-antigen specific manner and influence the
ultimate adaptive immune response in a manner that is yet to
be understood. The immune response to priming with DNA
plasmids encoding antigen results in the generation of an
antigen-specific adaptive immune response, which shapes the
nature of the immune response to subsequent boosts, in
concert with the action of adjuvants on innate immune
pathways. That we observe this difference at such an early
time point after boosting immunization may be suggestive of a
memory response. Indeed, this data prompts further questions
about how DNA vaccines act on innate and adaptive immunity,
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as well as how both the encoded antigen and the DNA itself act
to shape a setting for subsequent heterologous boosts.
A few notable exceptions to this trend were observed. In
mice immunized with protein formulated with MPLA, the
markers G-CSF and RANTES, associated with MPLA in the
context of the full DP6-001 regimen, were apparently
uncompromised in the absence of DNA priming. In addition, the
neutrophil chemoattractant KC remained at relatively
unchanged levels in the context of formulations containing
QS-21, MPLA, or ISCOMATRIX™ adjuvant, regardless of
vaccination strategy. This observation suggests that an early
immune response to vaccination characterized by strong
neutrophilia was common to all tested vaccine strategies and
adjuvants, and was minimally impacted by the presence or
absence of DNA priming.
The current study also suggested that while trace amount of
endotoxin contaminants will lead to elevated levels of only a
few cytokines, this has a minimal effect on the overall levels of
Env-specific antibody responses. These findings ruled out the
potential contribution of endotoxin contamination to vaccine-
induced immunogenicity and the observed profiles of non-
antigen specific serum cytokines. This analysis confirmed that
the adjuvant effects we observed with our various DP6-001
formulations were related to the adjuvant used, and not
potentiated by method of DNA preparation.
In summary, we have reported that two potent candidate
adjuvants MPLA and ISCOMATRIX™ adjuvant demonstrate
comparable immunogenicity to our previously employed
adjuvant QS-21, in the context of a heterologous, multiclade
HIV-1 Env DNA prime-protein boost regimen. However, these
adjuvants differ considerably in terms of induction of pro-
inflammatory cytokines and chemokines responsible for local
and systemic immune cell recruitment. This study provides
critical insight about these adjuvants in formulation with Env
antigen, as well as in the context of a DNA-primed immune
system. In addition, the distinct cytokine and chemokine
profiles defined for each adjuvant shed light on useful
correlates of vaccine immunogenicity as well as pro-
inflammatory markers of reactogenicity for guidance in adjuvant
selection for optimized Env prime-boost formulations.
Supporting Information
Figure S1.  Magnitude of Env-specific CD4+ and CD8+ T cell
responses induced by DP6-001 immunization and
adjuvants in C57Bl/6 wild type mice. Cytokines were
analyzed in murine splenocytes 7 days after final protein boost.
Spleens were harvested at termination 7 days after the final
protein boost. Splenocytes were cultured for 5 hours either
receiving the stimulation of a consensus HIV-1 gp120 Clade B
peptide pool (‘Env-B’) or media (‘baseline’). Env-specific
cytokine production by T cells was quantified by intracellular
cytokine staining and samples were run on an LSR II FACS
machine. Data was analyzed using FlowJo software. Shown is
the production of (A) IFNγ, (B) IL-2, and (C) IL-6 by CD4+ T
cells, and (D) IFNγ by CD8+ T cells in mice vaccinated with
DP6-001 and candidate adjuvants. Statistical comparisons
between adjuvant groups were performed with a one-way
ANOVA and Tukey post-test. Statistical significance of antigen-
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